ACD SOLUTION MODIFIED solution

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)

Disponible depuis:

AnazaoHealth Corporation

DCI (Dénomination commune internationale):

ANHYDROUS CITRIC ACID

Composition:

ANHYDROUS CITRIC ACID 8 mg in 1 mL

Mode d'administration:

INTRAVENOUS

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

ACD solution modified is to be used in the labeling of red blood cells for intravenous administration with Cr-51 Sodium Chromate. There are no known contraindications.

Statut de autorisation:

unapproved drug other

Résumé des caractéristiques du produit

ACD SOLUTION MODIFIED - ACD SOLUTION MODIFIED SOLUTION
ANAZAOHEALTH CORPORATION
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
ACD SOLUTION MODIFIED
Per your order, we have compounded ACD Solution Modified as a solution
of 10 mL in a 100 mL vial.
The characteristics of this compounded preparation are as follows
DESCRIPTION
Each 100 mL vial contains 80 mg citric acid, 224 mg sodium citrate
anhydrous, and 120 mg dextrose
anhydrous in a sterile, non-pyrogenic solution of 10 mL. The pH of the
solution has been adjusted to be
between 4.5 to 5.5
CLINICAL PHARMACOLOGY
In vitro, citrate ions combine with ionic calcium in the blood and the
resulting
lack of ionic calcium prevents coagulation. Blood that has been
treated with citrate anticoagulants is
nontoxic to the body when injected in small amounts intravenously.
After injection, citrate ions are
rapidly removed from the blood by the liver, polymerized into glucose,
and then metabolized in the
usual manner
INDICATIONS AND USAGE
ACD solution modified is to be used in the labeling of red blood cells
for intravenous administration
with Cr-51 Sodium Chromate.
CONTRAINDICATIONS
There are no known contraindications.
DOSAGE AND ADMINISTRATION
RED BLOOD CELL LABELING PROCEDURE
1. Labeling may be performed without washing or centrifugation steps
directly in the reaction vial.
2. A 30 to 50 mL sample of whole blood is withdrawn from the patient
and added aseptically to a vial
of ACD Solution Modified.
3. 50 to 150 microcuries of Sodium Chromate 51 is then injected into
the reaction vial using a shielded
syringe. The amount of radioactivity added to the vial will
depend on the intended use of the labeled red blood cells.
4. The suspension is incubated for 30 to 60 minutes at room
temperature with frequent, gentle
agitation.
5. After incubation, 100 mg Ascorbic Acid Injection is injected into
the vial. The ascorbic acid
reduces any r